EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Benchmarking of a multi‐biomarker low‐volume panel for Alzheimer's disease and related dementia research

Laura Ibanez iD, Menghan Liu, Aleksandra Beric, Jigyasha Timsina, Pat Kohlfeld, Kristy Bergmann, Joey Lowery, Nick Sykora, Brenda Sanchez-Montejo, Will Brock, John P Budde, Randall J Bateman und 10 weitere

Alzheimer's & Dementia · 2025-02 · 21 (2)

DOI: 10.1002/alz.14413 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 22.11.2024. Verfasst von Laura Ibanez und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Biomarkers, Alzheimer Disease, Amyloid beta-Peptides, Benchmarking. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NIH HHS, Alzheimer's Association Zenith Fellows Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION In the research setting, obtaining accurate established biomarker measurements and maximizing use of the precious samples is key. Accurate technologies are available for Alzheimer's disease (AD), but no platform can measure all the established and emerging biomarkers in one run. The NUcleic acid Linked Immuno‐Sandwich Assay (NULISA) is a technology that requires 15 µL of sample to measure more than 100 analytes. METHODS We compared AD‐relevant biomarkers included in the NULISA against validated assays in cerebrospinal fluid (CSF) and plasma. RESULTS CSF measures of amyloid beta 42/40, and phosphorylated tau (p‐tau)217 are highly correlated when measured by immunoassay, mass spectrometry, or NULISA. In plasma, p‐tau217 performance is similar to that reported with other technologies when predicting amyloidosis. Other biomarkers show a wide range of correlation values depending on the fluid and the platform. DISCUSSION The NULISA multiplexed platform produces reliable results for established biomarkers in CSF that are useful in research settings, with the advantage of measuring additional biomarkers using minimal sample volume. Highlights We tested the novel technology NUcleic acid Linked Immuno‐Sandwich Assay (NULISA) in the dementia research setting. NULISA multiplexed platform produces reliable results for established and emerging biomarkers using minimal sample volume. Cerebrospinal fluid measures of amyloid beta 42/40, and phosphorylated tau (p‐tau)217 are highly correlated when measured by immunoassay, mass spectrometry, or NULISA. In plasma, p‐tau217 performance is similar to that reported with other technologies when predicting amyloidosis. NULISA measures are useful in research settings, with the advantage of measuring additional biomarkers using minimal sample volume.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersAlzheimer DiseaseAmyloid beta-PeptidesBenchmarkingDementiaHumanstau ProteinsPeptide FragmentsFemaleMaleAgedImmunoassay

Stichwörter der Autor:innen

NUcleic acid Linked Immuno‐Sandwich Assayamyloidosis biomarkersbiomarkersmultiplex

Substanzen

Biomarkerstau ProteinsAmyloid beta-PeptidesPeptide Fragments

Autor:innen und Institutionen

  • Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Hope Center for Neurologic Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.
  • The Tracy Family SILQ Center, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.

ORCID-Profile: Laura Ibanez

Förderung

  • NIA NIH HHS
  • NIH HHS
  • Alzheimer's Association Zenith Fellows Award
  • Anonymous foundation
  • Zenith Fellows Award
  • BrightFocus Foundation
  • Michael J. Fox Foundation for Parkinson's Research
  • Alzheimer's Drug Discovery Foundation

Zitieren

APA

Ibanez, L., Liu, M., Beric, A., Timsina, J., Kohlfeld, P., Bergmann, K., Lowery, J., Sykora, N., Sanchez-Montejo, B., Brock, W., Budde, J. P., Bateman, R. J., Barthelemy, N., Schindler, S. E., Holtzman, D. M., Benzinger, T. L. S., Xiong, C., Tarawneh, R., Moulder, K., …, & Cruchaga, C. (2025). Benchmarking of a multi‐biomarker low‐volume panel for Alzheimer's disease and related dementia research. Alzheimer's & Dementia, 21(2). https://doi.org/10.1002/alz.14413

Vancouver

Ibanez L, Liu M, Beric A, Timsina J, Kohlfeld P, Bergmann K, et al. Benchmarking of a multi‐biomarker low‐volume panel for Alzheimer's disease and related dementia research. Alzheimer's & Dementia. 2025;21(2). doi:10.1002/alz.14413

BibTeX
@article{Ibanez2025,
  author = {Ibanez, Laura and Liu, Menghan and Beric, Aleksandra and Timsina, Jigyasha and Kohlfeld, Pat and Bergmann, Kristy and Lowery, Joey and Sykora, Nick and Sanchez-Montejo, Brenda and Brock, Will and Budde, John P and Bateman, Randall J and Barthelemy, Nicolas and Schindler, Suzanne E and Holtzman, David M and Benzinger, Tammie L S and Xiong, Chengjie and Tarawneh, Rawan and Moulder, Krista and Morris, John C and Sung, Yun Ju and Cruchaga, Carlos},
  title = {Benchmarking of a multi‐biomarker low‐volume panel for Alzheimer's disease and related dementia research},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {2},
  doi = {10.1002/alz.14413}
}
Kostenlos starten →